sellWeak cluster of 3
Jerome Charles Bressi sold $9,269 of FATE
See Remarks at FATE THERAPEUTICS INC. 5,980 shares at an average of $1.55, traded Jan 10, 2025, filed Jan 13, 2025.
Warning score
30Value
$9,269
5,980 shares
Holdings after
270,203
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$9k at market
- 0Share of holdings soldSold 2.2% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-25-004825, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 10, 2025 | SOpen-market sale Common Stock | -5,980 | $1.55 | $9,269 | 270,203 | Jan 13, 2025 |
Related signals
Other insiders at FATE THERAPEUTICS INC and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 40Moderate | sell 3 | FATE FATE THERAPEUTICS INC | Bahram Valamehr President and CEO | $13k | 8,705 | |
| 30Weak | sell 3 | FATE FATE THERAPEUTICS INC | Cindy Tahl See Remarks | $8,764 | 5,654 | |
| 35Weak | buy | FATE FATE THERAPEUTICS INC | Redmile Group, LLC director, owner | $669k | 397,964 | |
| 34Weak | sell | FATE FATE THERAPEUTICS INC | Redmile Group, LLC director, owner | $574k | 341,633 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.